STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Tóm tắt
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC.
Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR.
See related commentary by Etxeberria et al., p. 794.
This article is highlighted in the In This Issue feature, p. 781
Từ khóa
Tài liệu tham khảo
Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824
Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7
Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643
Carbone, 2017, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493
Langer, 2016, Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol, 17, 1497, 10.1016/S1470-2045(16)30498-3
Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X
Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0
Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627
Topalian, 2016, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat Rev Cancer, 16, 275, 10.1038/nrc.2016.36
Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954
Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011
Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774
Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348
Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498
Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095
Imielinski, 2012, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing, Cell, 150, 1107, 10.1016/j.cell.2012.08.029
Cancer Genome Atlas Research Network, 2014, Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385
Skoulidis, 2015, Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities, Cancer Discov, 5, 860, 10.1158/2159-8290.CD-14-1236
Shackelford, 2009, The LKB1-AMPK pathway: metabolism and growth control in tumour suppression, Nat Rev Cancer, 9, 563, 10.1038/nrc2676
Koyama, 2016, STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment, Cancer Res, 76, 999, 10.1158/0008-5472.CAN-15-1439
Kadara, 2017, Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up, Ann Oncol, 28, 75, 10.1093/annonc/mdw436
Yu, 2015, Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas, J Thorac Oncol, 10, 431, 10.1097/JTO.0000000000000432
Arbour, 2018, Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer, Clin Cancer Res, 24, 334, 10.1158/1078-0432.CCR-17-1841
Bonanno, 2017, LKB1 expression correlates with increased survival in patients with advanced non-small cell lung cancer treated with chemotherapy and bevacizumab, Clin Cancer Res, 23, 3316, 10.1158/1078-0432.CCR-16-2410
Facchinetti, 2017, LKB1/STK11 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value, Lung Cancer, 112, 62, 10.1016/j.lungcan.2017.08.002
Kim, 2017, CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells, Nature, 546, 168, 10.1038/nature22359
Tang, 2013, A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients, Clin Cancer Res, 19, 1577, 10.1158/1078-0432.CCR-12-2321
Kaufman, 2017, A transcriptional signature identifies LKB1 functional status as a novel determinant of MEK sensitivity in lung adenocarcinoma, Cancer Res, 77, 153, 10.1158/0008-5472.CAN-16-1639
Spranger, 2015, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404
Rizvi, 2018, Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand (PD-L)-ligand 1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J Clin Oncol, 36, 633, 10.1200/JCO.2017.75.3384
Chang, 2015, Metabolic competition in the tumor microenvironment is a driver of cancer progression, Cell, 162, 1229, 10.1016/j.cell.2015.08.016
Kottakis, 2016, LKB1 loss links serine metabolism to DNA methylation and tumorigenesis, Nature, 539, 390, 10.1038/nature20132
Kortlever, 2017, Myc cooperates with Ras by programming inflammation and immune suppression, Cell, 171, 1301, 10.1016/j.cell.2017.11.013
Tsai, 2015, The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss, Oncogene, 34, 1641, 10.1038/onc.2014.118
Tauriello, 2018, TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis, Nature, 554, 538, 10.1038/nature25492
Moren, 2011, Negative regulation of TGFbeta signaling by the kinase LKB1 and the scaffolding protein LIP1, J Biol Chem, 286, 341, 10.1074/jbc.M110.190660
Peng, 2016, Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov, 6, 202, 10.1158/2159-8290.CD-15-0283
Liu, 2012, LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma, Cancer Cell, 21, 751, 10.1016/j.ccr.2012.03.048
Bottcher, 2018, NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control, Cell, 172, 1022, 10.1016/j.cell.2018.01.004
Cao, 2015, Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer, J Natl Cancer Inst, 107, 358, 10.1093/jnci/dju358
Gajewski, 2015, The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment, Semin Oncol, 42, 663, 10.1053/j.seminoncol.2015.05.011
Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat Immunol, 14, 1014, 10.1038/ni.2703
Tang, 2016, Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade, Cancer Cell, 30, 500, 10.1016/j.ccell.2016.08.011
Corrales, 2015, Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity, Cell Rep, 11, 1018, 10.1016/j.celrep.2015.04.031
Horn, 2017, Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057), J Clin Oncol, 35, 3924, 10.1200/JCO.2017.74.3062
Meric-Bernstam, 2015, Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials, J Clin Oncol, 33, 2753, 10.1200/JCO.2014.60.4165
Wagle, 2012, High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing, Cancer Discov, 2, 82, 10.1158/2159-8290.CD-11-0184
Zehir, 2017, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med, 23, 703, 10.1038/nm.4333
Zheng, 2014, Anchored multiplex PCR for targeted next-generation sequencing, Nat Med, 20, 1479, 10.1038/nm.3729
Lanman, 2015, Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA, PLoS One, 10, e0140712, 10.1371/journal.pone.0140712
Lih, 2017, Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial, J Mol Diag, 19, 313, 10.1016/j.jmoldx.2016.10.007
Frampton, 2013, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, 31, 1023, 10.1038/nbt.2696